Ekso Bionics Holdings, Inc. (EKSO)
NASDAQ: EKSO · Real-Time Price · USD
3.490
+0.010 (0.29%)
At close: Aug 1, 2025, 4:00 PM
3.480
-0.010 (-0.29%)
After-hours: Aug 1, 2025, 6:52 PM EDT
CTI BioPharma Stock Forecast
EKSO's stock price has decreased by -77.84% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $34.75, which forecasts a 895.70% increase in the stock price over the next year. The lowest target is $9.50 and the highest is $60.
Price Target: $34.75 (+895.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Maintains $15 → $9.5 | Strong Buy | Maintains | $15 → $9.5 | +172.21% | Jul 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $135 → $60 | Strong Buy | Maintains | $135 → $60 | +1,619.20% | May 6, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $30 → $15 | Strong Buy | Maintains | $30 → $15 | +329.80% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +3,768.19% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +3,768.19% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
17.96M
from 17.93M
Increased by 0.20%
Revenue Next Year
25.56M
from 17.96M
Increased by 42.29%
EPS This Year
-5.51
from -8.43
EPS Next Year
-3.60
from -5.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 19.1M | 28.2M | 30.8M |
| Avg | 18.0M | 25.6M | 30.0M |
| Low | 16.7M | 22.7M | 28.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 6.7% | 57.3% | 20.6% |
| Avg | 0.2% | 42.3% | 17.2% |
| Low | -7.1% | 26.6% | 12.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -5.35 | -3.47 | -2.05 |
| Avg | -5.51 | -3.60 | -1.99 |
| Low | -5.59 | -3.68 | -1.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.